Pipeline Highlights - MP0712 (212Pb x DLL3) IND-enabling studies completed, IND filed[15] - Strategic collaboration with Orano Med expanded to ten 212Pb programs[15] - Lead candidate MP0726 targeting mesothelin (MSLN) nominated based on pre-clinical data[15] - Improved response rate and antitumor activity in low disease burden patients of ongoing Phase 1/2a reported for MP0533 at EHA 2025[15] - Study protocol approved for combo IIT with standard-of-care in cholangiocarcinoma for Switch-DARPin MP0317[15] Financial Position - The company has CHF ~105 million in cash as of September 30, 2025[8, 15] - The company is financed until 2028 through key value inflection points[8] MP0712 Radio-DARPin Therapy - MP0712 induces complete and durable tumor regression in NCI-H82 tumor model at 10 µCi injected every week[27] - Phase 1 study is expected to start in H2 2025, with initial safety and efficacy data in 2026[32] MP0533 Tetra-specific T-cell Engager for AML - In DR 8, 3 of 8 evaluable patients responded after cycle 1: 1 CR and 2 CRh as best overall response[62] - In DR 1-7, 12% (4) patients had response rate, while in DR 8, 37.5% (3) patients had response rate[69]

Core Insights - Molecular Partners AG is advancing its clinical-stage pipeline, focusing on DARPin therapeutics, with significant developments in its Radio-DARPin programs and T-cell engagers [1][2][3] Research & Development Highlights - The IND application for MP0712, a Radio-DARPin targeting DLL3 for small cell lung cancer, has been filed, with a Phase 1 trial expected to start by the end of 2025 [3][7] - Initial clinical imaging data for MP0712 will be presented in November, showcasing its application in compassionate care in South Africa [2][5] - MP0533, a multispecific T-cell engager for acute myeloid leukemia (AML), has shown promising results, with over 30% of evaluable patients achieving a clinical response [10][12] - The company is exploring further dosing strategies for MP0533 to enhance patient outcomes and is planning to present updated data at the ASH Annual Meeting in December [11][12] - MP0317, a tumor-localized agonist, is undergoing an investigator-initiated trial for advanced cholangiocarcinoma, with a focus on progression-free survival [13][14] Corporate Governance Highlights - Martin Steegmaier, Ph.D., has been appointed as Chief Scientific Officer, bringing extensive oncology drug development experience [17] Financial and Business Outlook - For 2025, the company anticipates total operating expenses of CHF 55-60 million, with sufficient cash reserves of CHF 105 million to fund operations until 2028 [18][19]

Core Insights - Molecular Partners AG is making significant progress in its clinical programs, particularly with MP0712 and MP0533, with key milestones expected in the near future [2][6] - The company has appointed Martin Steegmaier, Ph.D., as Chief Scientific Officer, enhancing its leadership team [2][15] - Financially, the company is in a strong position with cash reserves projected to last until 2028 [2][19] Research & Development Highlights - MP0533 is in a Phase 1/2a trial for acute myeloid leukemia, showing promising results with over 30% of evaluable patients achieving a clinical response [3][4] - The dosing regimen for MP0533 has been optimized to enhance patient responses, with initial data from cohort 9 expected in Q4 2025 [5][6] - MP0712, a Radio-DARPin therapy for small cell lung cancer, is preparing for an IND filing, with initial clinical data anticipated in H1 2026 [8][9] Corporate Governance Highlights - The appointment of Martin Steegmaier, Ph.D., as CSO is aimed at strengthening the company's focus on oncology drug development [15] - A strategic review led to a planned reduction of up to 40 positions, which is expected to improve operational efficiency and extend the cash runway into 2028 [16] Financial and Business Outlook - For 2025, the company expects total operating expenses between CHF 55-65 million, with a significant portion being non-cash costs [18] - As of June 30, 2025, cash and cash equivalents totaled CHF 114 million, sufficient to fund operations into 2028 [19]

Core Insights - Molecular Partners AG is advancing its clinical programs and expects to achieve key milestones in 2025, including the IND filing and initial clinical data for its lead program MP0712 [2][5][8] - The company has a strong financial position with cash reserves of CHF 131 million as of March 31, 2025, which is projected to fund operations well into 2027 [19] Research & Development Highlights - The strategic partnership with Orano Med has been expanded to co-develop up to ten Pb-labeled radiotherapy programs, including MP0712 targeting DLL3 for small cell lung cancer [3][8] - Preclinical data for MP0712 presented at the AACR 2025 showed high tumor uptake and a favorable toxicity profile, supporting its efficacy in mouse models [4][9] - The IND application for MP0712 is planned for mid-2025, with a Phase 1 dose-escalation study set to begin in the second half of 2025 [5][8] - The second RDT program targeting MSLN is also in development, with promising preclinical data indicating effective binding despite high shedding of MSLN [7][9] Clinical Programs - MP0533, a multispecific T cell engager, is in a Phase 1/2a trial for acute myeloid leukemia, with recent data showing increased response rates in cohort 8 [10][11] - The study protocol for MP0533 has been amended to enhance exposure and response rates, with additional data expected in 2025 [12] - The Switch-DARPin platform aims to improve T cell engagers' safety and potency, with preclinical proof-of-concept data presented at AACR 2025 [13] Financial and Business Outlook - The company anticipates total operating expenses of CHF 55-65 million for 2025, with a portion allocated to non-cash effective costs [18] - The current cash position is expected to support operational needs and capital expenditures through 2027 [19] Corporate Governance Highlights - All motions proposed by the Board of Directors at the Annual General Meeting in April 2025 were approved by shareholders [17]